Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in ABBV — AbbVie Inc.

CIK 886982 NEW YORK, NY
Back to ABBV Full portfolio

Position in ABBV

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$3,293,946,727
+$324,576,373 QoQ
Shares Held
15,145,279
+16.5% QoQ
Ownership
0.857%
of shares outstanding
% of Portfolio
0.52%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 93.83695118215047.ToString("F0")% Shared 0.ToString("F0")% None 6.163048817849521.ToString("F0")%

Common Shares in ABBV Over Time

Shares Held

Position Value (USD)

Derivatives in ABBV

reported options exposure · as of Mar 31, 2026
CallValue
$117,770,835
CallShares
541,500
PutValue
$163,313,241
PutShares
750,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $25,307,344,615 across 17 Drug Manufacturers - General names. ABBV ranks #3 (13.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 6,340,865 $5,832,137,397
2 JNJ
Johnson & Johnson
 18,057,047 $4,413,864,566
3 ABBV
AbbVie Inc.
This page 		15,145,279 $3,293,946,727
4 MRK
Merck & Co., Inc.
 20,133,379 $2,421,844,158
5 AZN
Astrazeneca PLC
 10,605,842 $2,091,684,157
6 GILD
Gilead Sciences, Inc.
 11,065,214 $1,542,158,873
7 AMGN
Amgen Inc
 4,219,989 $1,484,803,127
8 PFE
Pfizer Inc
 47,105,556 $1,322,724,010

All Filings in ABBV

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $3,293,946,727 15,145,279
2026-03-31 $163,313,241 750,900
2026-03-31 $117,770,835 541,500
2025-12-31 $53,603,754 234,600
2025-12-31 $123,544,543 540,700
2025-12-31 $2,969,370,354 12,995,625
2025-09-30 $72,055,248 311,200
2025-09-30 $3,101,529,004 13,395,219
2025-09-30 $40,774,194 176,100
2025-06-30 $66,693,266 359,300
2025-06-30 $2,258,709,914 12,168,462
2025-06-30 $33,040,360 178,000
2025-03-31 $59,734,152 285,100
2025-03-31 $2,964,709,674 14,150,008
2025-03-31 $44,376,336 211,800
2024-12-31 $50,058,090 281,700
2024-12-31 $20,293,340 114,200
2024-12-31 $2,007,160,769 11,295,221
2024-09-30 $114,439,660 579,500
2024-09-30 $2,109,544,354 10,682,319
2024-09-30 $71,941,964 364,300
2024-06-30 $59,568,896 347,300
2024-06-30 $63,205,120 368,500
2024-06-30 $1,991,499,679 11,610,889
2024-03-31 $137,485,500 755,000
2024-03-31 $63,953,520 351,200
2024-03-31 $1,618,104,360 8,885,801
2023-12-31 $57,152,936 368,800
2023-12-31 $1,645,850,514 10,620,446
2023-12-31 $68,093,818 439,400
2023-09-30 $1,600,021,068 10,734,074
2023-09-30 $87,080,852 584,200
2023-09-30 $81,625,256 547,600
2023-06-30 $1,255,727,923 9,320,329
2023-06-30 $65,761,713 488,100
2023-06-30 $39,408,525 292,500
2023-03-31 $40,958,090 257,000
2023-03-31 $1,612,737,380 10,119,454
2023-03-31 $68,624,722 430,600
2022-12-31 $46,802,256 289,600
2022-12-31 $1,428,173,102 8,837,158
2022-12-31 $194,336,025 1,202,500
2022-09-30 $27,727,786 206,600
2022-09-30 $21,782,283 162,300
2022-09-30 $1,263,143,986 9,411,698
2022-06-30 $34,323,156 224,100
2022-06-30 $1,319,501,121 8,615,181
2022-06-30 $40,005,392 261,200
2022-03-31 $1,495,615,023 9,225,927
2022-03-31 $65,832,871 406,100

Report a Problem

Category
Description
Email (optional, for follow-up)